Skip to main content

Drug Safety

    Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…
    An update on JAK inhibitors and cardiovascular risks

    Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments
    10 months 1 week ago
    An update on JAK inhibitors and cardiovascular risks Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors. https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
    EULAR 2023 Day 4 Recap
    Some subjects in rheumatology seem to create contention the more they get explored, and one of those areas is a traditional crowd favourite for discussion at EULAR - clinically suspect arthralgias.…
    Upadacitinib in SLE
    Daily Recap: Day Three EULAR 2023
    #EULAR23 – Day 2 Report

    Day 2 at the international EULAR Congress meeting is always bigger and busier. There are mo
    10 months 1 week ago
    #EULAR23 – Day 2 Report Day 2 at the international EULAR Congress meeting is always bigger and busier. There are more sessions to choose from and more audience questions in the big auditorium presentations. https://t.co/vjrG7ez2fX https://t.co/HUuDImzqZA